Skip to main content
. 2023 Jan 30;43(1):BSR20220893. doi: 10.1042/BSR20220893

Figure 2. ZJP drug-disease target convergence map.

Figure 2

(A) Target map of effective active components of ZJP. The darker the color, the larger the node and the higher the degree. (B1) Oral-bioavailability. (B2) Drug-likeness. (B3) Drug Blood–brain barrier penetration. (B4) Drug half-life.